Anti-SCE1 antibody

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SCE1 also known as SUMO-Conjugating Enzyme 1 functions as an enzyme that transfers SUMO (Small Ubiquitin-like Modifier) proteins to target substrates an important step in the SUMOylation process. This protein exhibits a molecular mass of approximately 29 kDa. SCE1 is expressed in various tissues with notable levels observed in the nucleus of eukaryotic cells. Its responsibility includes the modification of other proteins by catalyzing the attachment of SUMO which affects the target proteins' function stability and localization.

Biological function summary

The SUMOylation process involving SCE1 plays a critical role in DNA repair transcriptional regulation and cell cycle control. As part of a SUMOylation complex SCE1 interacts with several other proteins to mediate these regulatory functions. The modification of proteins by SCE1 affects their interaction capabilities subcellular localization and can alter their stability making it important for cellular stress responses particularly under conditions that perturb the genome.

Pathways

SCE1 is essential in the SUMOylation pathway and integrates into essential cellular mechanisms such as the DNA damage response and transcriptional silencing. In these pathways the interplay between SCE1 and proteins like UBC9 (another SUMO-conjugating enzyme) and PIAS (protein inhibitor of activated STAT) family members is necessary. These interactions highlight its role in maintaining genomic stability and regulating gene expression important for proper cellular function.

Aberrant SCE1 activity has connections to cancer and neurodegenerative diseases. In cancer dysregulated SUMOylation mediated by SCE1 can contribute to defective cell cycle control and evasion of apoptosis often connecting with proteins like p53. In neurodegenerative diseases abnormal protein modifications through SUMOylation may impair neuronal function linking SCE1 to pathological proteins involved in such disorders. Understanding its involvement in these conditions aids in the development of potential therapeutic strategies targeting the SUMOylation pathway.